172 related articles for article (PubMed ID: 38905039)
1. Immunogenicity of biologics used in the treatment of asthma.
Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
Hum Antibodies; 2024 Jun; ():. PubMed ID: 38905039
[TBL] [Abstract][Full Text] [Related]
2. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
3. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
Cheng SL
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
6. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
7. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
9. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
10. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
Mavissakalian M; Brady S
Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
[TBL] [Abstract][Full Text] [Related]
12. A pragmatic guide to choosing biologic therapies in severe asthma.
Kavanagh JE; Hearn AP; Jackson DJ
Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
[TBL] [Abstract][Full Text] [Related]
13. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
Park S; Kim Y; Lee GH; Choi SA
Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
[TBL] [Abstract][Full Text] [Related]
14. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
15. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
Menzies-Gow A; Wechsler ME; Brightling CE
Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
[TBL] [Abstract][Full Text] [Related]
16. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic respiratory disorders and the impact of biologics.
Bernstein JS; Wechsler ME
Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
[TBL] [Abstract][Full Text] [Related]
18. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
20. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]